摘要
目的:系统评价羟氯喹补充治疗IgA肾病的有效性和安全性。方法:检索中英文电子数据库,纳入联合或单用羟氯喹对比常规治疗IgA肾病的有效性、安全性的研究。结局指标为尿蛋白缓解率、尿蛋白定量、不良反应发生率、估算肾小球滤过率和血肌酐水平,使用Revman 5.4软件进行数据分析。结果:最终纳入8项研究,包括737例患者。Meta分析结果显示,常规治疗联合羟氯喹比对照组达到更高的尿蛋白缓解率(总有效率)(RR=2.26,95%CI:1.08~4.75,P=0.03),更低的尿蛋白定量(SMD=-0.61,95%CI:-1.09~-0.13,P=0.01),2组不良反应发生率差异无统计学意义(RR=1.76,95%CI:0.50~6.15,P=0.38)。结论:现有证据显示,对于IgA肾病患者,与常规治疗相比,联合羟氯喹补充治疗的疗效更佳,且不增加不良反应的发生。
OBJECTIVE To systematically evaluate the efficacy and safety of hydroxychloroquine supplementation treatment on IgA nephropathy.METHODS Chinese and English electronic databases were searched to include the studies on the efficacy and safety of Hydroxychloroquine supplementation treatment versus conventional treatment of IgA nephropathy.Outcome measures included proteinuria remission rate,urinary protein quantification,incidence of adverse events,estimated glomerular filtration rate,and serum creatinine level.Revman 5.4 software was used for data analysis.RESULTS A total of 9 studies with 917 patients were included.The Meta analysis showed that compared with the conventional treatment group,the hydroxychloroquine supplementation treatment group achieved a significantly higher rate of proteinuria remission(RR=2.26,95%CI:1.08-4.75,P=0.03) and significantly lower urinary protein quantification(SMD=-0.61,95%CI:-1.09--0.13,P=0.01).There was no significant difference in the incidence rate of adverse events between the two groups(RR=1.76,95%CI:0.50-6.15,P=0.38).CONCLUSION The current evidence shows that for IgA nephropathy who have moderate to severe proteinuria,hydroxychloroquine supplementation treatment has a better effect than conventional treatment and does not increase the incidence rate of adverse events.
作者
彭露婷
黄志荣
官慧儿
秦又发
PENG Lu-ting;HUANG Zhi-rong;GUAN Hui-er;QIN You-fa(School of Pharmaceutical Sciences,Southern Medical University,Guangdong Dongguan 523326,China;Department of Clinical Pharmacy,SSL Central Hospital of Dongguan City,Affiliated Dongguan Shilong People’s Hospital of Southern Medical University,Guangdong Dongguan 523326,China)
出处
《中国医院药学杂志》
CAS
北大核心
2022年第14期1463-1468,共6页
Chinese Journal of Hospital Pharmacy
基金
广东省中医药局科研项目(编号:20201368)
东莞市新型冠状病毒肺炎防疫防治技术研究及推广应急攻关专项项目(编号:202071715024129)。
关键词
IGA肾病
羟氯喹
尿蛋白
META分析
IgA nephropathy
hydroxychloroquine
urinary protein
Meta-analysis
